Beranda › Limfoma
Uji klinis Limfoma yang merekrut di AS
142 studi untuk Limfoma merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Houston, TX34 studi
- New York City, NY33 studi
- Boston, MA33 studi
- Washington, DC23 studi
- Baldwin Park, CA21 studi
- Chicago, IL20 studi
- Durham, NC17 studi
- Philadelphia, PA15 studi
- St. Louis, MO15 studi
- Cleveland, OH14 studi
- Edison, NJ12 studi
- Atlanta, GA12 studi
- Seattle, WA12 studi
- Columbus, OH11 studi
- Nashville, TN11 studi
- Miami, FL11 studi
- Rochester, MN11 studi
- Salt Lake City, UT11 studi
- Queens, NY10 studi
- Pittsburgh, PA10 studi
- Los Angeles, CA10 studi
- Dallas, TX10 studi
- Mountain View, CA9 studi
- Portland, OR9 studi
- Greenburgh, NY9 studi
- Denver, CO9 studi
- Milwaukee, WI9 studi
- Staten Island, NY8 studi
- East Norwalk, CT8 studi
- Aurora, CO8 studi
- Cincinnati, OH8 studi
- Birmingham, AL8 studi
- New Rochelle, NY7 studi
- Tampa, FL7 studi
- San Antonio, TX7 studi
- Omaha, NE7 studi
- Phoenix, AZ7 studi
- New Haven, CT7 studi
- Kansas City, MO6 studi
- Cedar Rapids, IA6 studi
Berdasarkan negara bagian
- Alabama9 studi
- Arizona11 studi
- Arkansas3 studi
- California40 studi
- Colorado16 studi
- Connecticut7 studi
- Distrik Columbia7 studi
- Florida25 studi
- Georgia16 studi
- Illinois23 studi
- Indiana6 studi
- Iowa6 studi
- Kansas7 studi
- Kentucky5 studi
- Maryland21 studi
- Massachusetts33 studi
- Michigan12 studi
- Minnesota14 studi
- Missouri17 studi
- Nebraska7 studi
- New Jersey18 studi
- New York42 studi
- North Carolina22 studi
- Ohio29 studi
- Oklahoma4 studi
- Oregon9 studi
- Pennsylvania24 studi
- South Carolina4 studi
- Tennessee15 studi
- Texas45 studi
- Utah14 studi
- Virginia10 studi
- Washington12 studi
- Wisconsin12 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Rutgers University Study of the Genetics of Blood Cancers
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 hingga 110 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07714044Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Menerima pesertaStudi observasional
Usia 0 hingga 38 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06131801T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06343311A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Menerima pesertaFase 2
1 Month – 17 Years · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT04570423CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Menerima pesertaFase 1/2
Usia 3 hingga 39 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT05442515A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07192471A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07015242Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07583810Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT03418038Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Menerima pesertaFase 1/2
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT03223610Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07014293A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07013435Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
Menerima pesertaStudi observasional
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT00006518Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Menerima pesertaStudi observasional
Usia 18 hingga 110 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT00923507Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
Menerima pesertaStudi observasional
Usia 3 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT01441089A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Menerima pesertaFase 1/2
Hingga usia 25 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT04094610Epco, Zanu, Ritux for R/R FL or MZL
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06563596Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Menerima pesertaFase 1
24 Months – 18 Years · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06441331Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT02974647Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Menerima pesertaFase awal 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06398457CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
Menerima pesertaFase 2
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT04083495Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT04301076Precise Oncology Interventions in Nutrition and Training (OnPoint)
Menerima pesertaSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT06534918Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
Menerima pesertaFase 2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT03258567A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07221500Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.